Skip to main content
Top
Published in: Digestive Diseases and Sciences 2/2008

01-02-2008 | Original Paper

13C-Urea Breath Test Values and Helicobacter pylori Eradication

Authors: Angelo Zullo, Federico Perna, Chiara Ricci, Cesare Hassan, Andrea Tampieri, Vincenzo De Francesco, Sergio Morini, Dino Vaira

Published in: Digestive Diseases and Sciences | Issue 2/2008

Login to get access

Abstract

Delta over baseline (DOB) values of 13C-urea breath test (UBT) have been shown to be predictive of H. pylori eradication following therapy. This was a post hoc analysis of a large, double-blind, randomized trial. Consecutive patients with a positive UBT underwent upper endoscopy. H. pylori strains were tested for clarithromycin resistance. All patients received an eradication therapy with either a standard 10-day triple therapy or a 10-day sequential regimen. The infection was considered cured when two consecutive UBTs were negative. Basal DOB values were categorized as low (<16), intermediate (16–35), or high (>35). A total of 282 patients were selected. Eradication rates did not differ between patients with high and low DOB values. No significant difference in DOB values emerged between patients infected with clarithromycin-susceptible and clarithromycin-resistant strains. Under multivariate analysis, DOB values did not influence the bacterial eradication, which was significantly affected only by the presence of clarithromycin resistance. This large analysis failed to demonstrate a role for DOB value in H. pylori eradication with either a 10-day triple or sequential therapy.
Literature
1.
go back to reference Laine L, Fennerty MB, Osato M et al (2000) Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol 95:3393–3398PubMedCrossRef Laine L, Fennerty MB, Osato M et al (2000) Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol 95:3393–3398PubMedCrossRef
2.
go back to reference Vakil N, Lanza F, Schwartz H, Barth J (2004) Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 20:99–107PubMedCrossRef Vakil N, Lanza F, Schwartz H, Barth J (2004) Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 20:99–107PubMedCrossRef
3.
go back to reference Vakil N (2006) Helicobacter pylori treatment: a practical approach. Am J Gastroenterol 101:497–499PubMedCrossRef Vakil N (2006) Helicobacter pylori treatment: a practical approach. Am J Gastroenterol 101:497–499PubMedCrossRef
4.
go back to reference Zagari RM, Pozzato P, Martuzzi C et al (2005) 13C-urea breath test to assess Helicobacter pylori bacterial load. Helicobacter; 10:615–619PubMedCrossRef Zagari RM, Pozzato P, Martuzzi C et al (2005) 13C-urea breath test to assess Helicobacter pylori bacterial load. Helicobacter; 10:615–619PubMedCrossRef
5.
go back to reference Perri F, Clemente R, Pastore M et al (1998) The 13C-urea breath test as a predictor of intragastric bacterial load and severity of Helicobacter pylori gastritis. Scand J Clin Lab Invest 58:19–27PubMedCrossRef Perri F, Clemente R, Pastore M et al (1998) The 13C-urea breath test as a predictor of intragastric bacterial load and severity of Helicobacter pylori gastritis. Scand J Clin Lab Invest 58:19–27PubMedCrossRef
6.
go back to reference Sheu BS, Lee SC, Yang HB et al (1999) Quantitative result of 13C urea breath test at 15 minutes may correlate with the bacterial density of H. pylori in the stomach. Hepatogastroenterology 46:2057–2062PubMed Sheu BS, Lee SC, Yang HB et al (1999) Quantitative result of 13C urea breath test at 15 minutes may correlate with the bacterial density of H. pylori in the stomach. Hepatogastroenterology 46:2057–2062PubMed
7.
go back to reference Kobayashi D, Eishi Y, Ohkusa T et al (2002) Gastric mucosal density of Helicobacter pylori estimated by real-time PCR compared with results of urea breath test and histological grading. J Med Microbiol 51:305–311PubMed Kobayashi D, Eishi Y, Ohkusa T et al (2002) Gastric mucosal density of Helicobacter pylori estimated by real-time PCR compared with results of urea breath test and histological grading. J Med Microbiol 51:305–311PubMed
8.
go back to reference Moshkowitz M, Konikoff FM, Peled Y et al (1995) High Helicobacter pylori numbers are associated with low eradication rate after triple therapy. Gut 36:845–847PubMedCrossRef Moshkowitz M, Konikoff FM, Peled Y et al (1995) High Helicobacter pylori numbers are associated with low eradication rate after triple therapy. Gut 36:845–847PubMedCrossRef
9.
go back to reference Perri F, Clemente R, Festa V et al (1998) Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori. Ital J Gastroenterol Hepatol 30:146–150PubMed Perri F, Clemente R, Festa V et al (1998) Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori. Ital J Gastroenterol Hepatol 30:146–150PubMed
10.
go back to reference Lai YC, Yang JC, Huang SH (2004) Pre-treatment urea breath test results predict the efficacy of Helicobacter pylori eradication therapy in patients with active duodenal ulcers. World J Gastroenterol 10:991–994PubMed Lai YC, Yang JC, Huang SH (2004) Pre-treatment urea breath test results predict the efficacy of Helicobacter pylori eradication therapy in patients with active duodenal ulcers. World J Gastroenterol 10:991–994PubMed
11.
go back to reference Maconi G, Parente F, Russo A et al (2001) Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol 96:359–366PubMed Maconi G, Parente F, Russo A et al (2001) Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol 96:359–366PubMed
12.
go back to reference Ahuja V, Bal CS, Sharma MP (1998) Can the C-14 urea breath test replace follow-up endoscopic biopsies in patients treated for Helicobacter pylori infection? Clin Nucl Med 23:815–819PubMedCrossRef Ahuja V, Bal CS, Sharma MP (1998) Can the C-14 urea breath test replace follow-up endoscopic biopsies in patients treated for Helicobacter pylori infection? Clin Nucl Med 23:815–819PubMedCrossRef
13.
go back to reference Cremonini F, Bartolozzi F, Armuzzi A et al (2005) Can 13C urea breath test predict resistance to therapy in Helicobacter pylori infection? Hepatogastroenterology 52:1119–1121PubMed Cremonini F, Bartolozzi F, Armuzzi A et al (2005) Can 13C urea breath test predict resistance to therapy in Helicobacter pylori infection? Hepatogastroenterology 52:1119–1121PubMed
14.
go back to reference Perri F, Villani MR, Festa V et al (2001) Predictors of failure of Helicobacter pylori eradication with the standard ‘Maastricht triple therapy’. Aliment Pharmacol Ther 15:1023–1029PubMedCrossRef Perri F, Villani MR, Festa V et al (2001) Predictors of failure of Helicobacter pylori eradication with the standard ‘Maastricht triple therapy’. Aliment Pharmacol Ther 15:1023–1029PubMedCrossRef
15.
go back to reference Gisbert JP, Olivares D, Jimenez I et al (2006) Is there any correlation between 13C-urea breath test values and response to first-line and rescue Helicobacter pylori eradication therapies? Dig Liver Dis 38:254–259PubMedCrossRef Gisbert JP, Olivares D, Jimenez I et al (2006) Is there any correlation between 13C-urea breath test values and response to first-line and rescue Helicobacter pylori eradication therapies? Dig Liver Dis 38:254–259PubMedCrossRef
16.
go back to reference Megraud F (2004) H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53:1374–1384PubMedCrossRef Megraud F (2004) H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53:1374–1384PubMedCrossRef
17.
go back to reference Vaira D, Zullo A, Vakil N et al (2007) Sequential therapy versus triple therapy for Helicobacter pylori eradication: a randomized trial. Ann Int Med 146:556–563PubMed Vaira D, Zullo A, Vakil N et al (2007) Sequential therapy versus triple therapy for Helicobacter pylori eradication: a randomized trial. Ann Int Med 146:556–563PubMed
18.
19.
go back to reference Zullo A, Sanchez-Mete L, Hassan C et al (2004) Helicobacter pylori density and cagA status in cirrhotic patients: a case–control study. J Gastroenterol Hepatol 19:1174–1178PubMedCrossRef Zullo A, Sanchez-Mete L, Hassan C et al (2004) Helicobacter pylori density and cagA status in cirrhotic patients: a case–control study. J Gastroenterol Hepatol 19:1174–1178PubMedCrossRef
20.
go back to reference Kao AW, Cheng HC, Sheu BS et al (2005) Posttreatment 13C-urea breath test is predictive of antimicrobial resistance to H. pylori after failed therapy. J Gen Intern Med 20:139–132PubMedCrossRef Kao AW, Cheng HC, Sheu BS et al (2005) Posttreatment 13C-urea breath test is predictive of antimicrobial resistance to H. pylori after failed therapy. J Gen Intern Med 20:139–132PubMedCrossRef
21.
go back to reference Lin CY, Liu CS, Ding HJ et al (2006) Positive correlation between standardized uptake values of FDG uptake in the stomach and the value of the 13C-urea breath test. Clin Nucl Med 31:792–794PubMedCrossRef Lin CY, Liu CS, Ding HJ et al (2006) Positive correlation between standardized uptake values of FDG uptake in the stomach and the value of the 13C-urea breath test. Clin Nucl Med 31:792–794PubMedCrossRef
22.
go back to reference Shmuely H, Yahav J, Samra Z et al (2007) Elevated 13C-urea breath test values females infected with Helicobacter pylori. Dig Dis Sci Jan 11, [Epub ahead of print] Shmuely H, Yahav J, Samra Z et al (2007) Elevated 13C-urea breath test values females infected with Helicobacter pylori. Dig Dis Sci Jan 11, [Epub ahead of print]
23.
go back to reference Franceschi F, Armuzzi A, Cremonini F et al (2002) Delta 13CO2 excretion and expression of dyspeptic symptoms in patients evaluated for Helicobacter pylori infection by 13C-urea breath test. Dig Dis Sci 47:804–808PubMedCrossRef Franceschi F, Armuzzi A, Cremonini F et al (2002) Delta 13CO2 excretion and expression of dyspeptic symptoms in patients evaluated for Helicobacter pylori infection by 13C-urea breath test. Dig Dis Sci 47:804–808PubMedCrossRef
24.
go back to reference Tseng CA, Wu JY, Pan YS et al (2005) Comparison of 13C-urea breath test values in gastric cancer, peptic ulcer and gastritis. Hepatogastroenterology 52:1636–1640PubMed Tseng CA, Wu JY, Pan YS et al (2005) Comparison of 13C-urea breath test values in gastric cancer, peptic ulcer and gastritis. Hepatogastroenterology 52:1636–1640PubMed
25.
go back to reference Sheu BS, Yang HB, Su IJ et al (1996) Bacterial density of Helicobacter pylori predicts the success of triple therapy in bleeding duodenal ulcer. Gastrointest Endosc 44:683–688PubMedCrossRef Sheu BS, Yang HB, Su IJ et al (1996) Bacterial density of Helicobacter pylori predicts the success of triple therapy in bleeding duodenal ulcer. Gastrointest Endosc 44:683–688PubMedCrossRef
26.
go back to reference Scaccianoce G, Hassan C, Panarese A et al (2006) Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with 10-day sequential regimen. Can J Gastroenterol 20:113–117PubMed Scaccianoce G, Hassan C, Panarese A et al (2006) Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with 10-day sequential regimen. Can J Gastroenterol 20:113–117PubMed
27.
go back to reference De Francesco V, Margiotta M, Zullo A et al (2006) Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 144:94–100PubMed De Francesco V, Margiotta M, Zullo A et al (2006) Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 144:94–100PubMed
Metadata
Title
13C-Urea Breath Test Values and Helicobacter pylori Eradication
Authors
Angelo Zullo
Federico Perna
Chiara Ricci
Cesare Hassan
Andrea Tampieri
Vincenzo De Francesco
Sergio Morini
Dino Vaira
Publication date
01-02-2008
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 2/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-9893-2

Other articles of this Issue 2/2008

Digestive Diseases and Sciences 2/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.